Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Durvalumab + Oleclumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 89 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).
Oleclumab MEDI9447 Adenosine Targeting 19 CD73 Antibody 10 Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03794544 Phase II Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + Monalizumab Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed USA | ITA | FRA | ESP | CAN 2
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Withdrawn CAN 0
NCT03833440 Phase II Ceralasertib + Durvalumab Durvalumab + Oleclumab Docetaxel Durvalumab + Monalizumab Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR) Recruiting FRA 0
NCT03822351 Phase II Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Active, not recruiting USA | ITA | FRA | ESP | CAN 4
NCT04262375 Phase II Durvalumab + Oleclumab A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) Withdrawn CAN 0
NCT04668300 Phase II Durvalumab + Oleclumab Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) Recruiting USA 0
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Active, not recruiting USA | ESP | CAN | BEL | AUT 5
NCT05061550 Phase II Durvalumab + Monalizumab Durvalumab + Oleclumab Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) Recruiting USA | ITA | FRA | ESP | CAN 2
NCT03773666 Phase I Durvalumab + Oleclumab Durvalumab A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Active, not recruiting USA 0
NCT05221840 Phase III Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) Recruiting USA | ITA | FRA | ESP | DEU | CAN 15
NCT03875573 Phase II Durvalumab Durvalumab + Oleclumab Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) Recruiting FRA | BEL 0


Additional content available in CKB BOOST